Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted
Thesis Summary

SQM entered the second half of 2026 with sharply improved operating momentum: first-half revenue more than doubled year over year, gross margin reached 48.2%, net income exceeded US$1.0 billion, and second-quarter lithium sales surpassed 84,000 metric tons LCE. Management also raised its 2026 global lithium-demand expectation to above 2.1 million metric tons. These indicators support a constructive operating outlook, supplemented by favorable iodine pricing and stronger Specialty Plant Nutrition activity. A Hold recommendation is nevertheless appropriate because the earnings rebound remains sensitive to lithium prices and demand, material expansion depends on permitting and execution.

Sign in / Sign up to read more
This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.
Street view · analyst 12-month targets18 analysts · as of 18 Aug 2026
Low · most bearish analyst$44.35
Mean target$84.78
High · most bullish analyst$110.00
Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026
Scenarios · 12-month scenario targetsAnchored at research date
Bear CaseDownside scenario
$44.3517%

Lithium demand or pricing reverses, quarterly sales fall below the first-quarter 2026 level, and gross margin retreats toward the 2025 baseline. Delayed Salar Futuro permitting or weaker non-lithium volumes would further reduce earnings resilience.

Base CaseCentral scenario
$84.7857%
Matches the consensus mean

Lithium demand remains healthy but pricing and margins normalize from the exceptionally strong first half. SQM maintains solid volumes across lithium, iodine and Specialty Plant Nutrition while progressing Salar Futuro permitting.

Bull CaseUpside scenario
$110.0026%

Lithium demand remains above management's 2.1-million-ton expectation, pricing continues to strengthen, and quarterly sales remain near or above the second-quarter record. Sustained utilization in Chile and Australia, combined with favorable iodine and Specialty Plant Nutrition conditions, preserves a gross margin materially above the 2025 level.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits
  • First-half 2026 revenue increased 103.4% year over year to US$4,228.5 million, while net income reached US$1,024.7 million.
  • Second-quarter lithium sales surpassed 84,000 metric tons LCE, and management increased its 2026 global demand expectation to above 2.1 million metric tons.
  • First-half gross margin expanded to 48.2%, compared with a 29.6% full-year margin in 2025.
  • Iodine achieved record pricing and quarterly revenue, while Specialty Plant Nutrition delivered strong volumes and pricing.
Sign in / Sign up to read more
Key Investment Risks
  • Lithium earnings remain exposed to changes in market pricing and demand; management attributed the second-quarter improvement partly to higher prices and stronger-than-expected demand.
  • The investment case depends on successful operation and expansion of lithium assets in Chile and Australia, including the Nova Andino Litio and Covalent Lithium partnerships.
  • Salar Futuro remained subject to environmental-permitting documentation and submission, creating timing and execution uncertainty.
  • SQM's Chilean operations have substantial fiscal and contractual obligations; more than US$1.6 billion of payments to the Chilean State were accrued in the first half of 2026.
Sign in / Sign up to read more

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Explore this dossier

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.